COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

• Authors: PAGANO Livio; SALMANTON-GARCÍA Jon; MARCHESI Francesco; LÓPEZ-GARCÍA Alberto; LAMURE Sylvain; ITRI Federico; GOMES-SILVA Maria; DRAGONETTI Giulia; FALCES-ROMERO Iker; DOESUM Jaap van; SILI Uluhan; LABRADOR Jorge; CALBACHO Maria; BILGIN Yavuz M; WEINBERGEROVÁ Barbora; SERRANO Laura; SUSANA José-María Ribera-Santa; MALAK Sandra; LOUREIRO-AMIGO José; GLENTHOJ Andreas; CÓRDOBA-MASCUNANO Raúl; NUNES-RODRIGUES Raquel; GONZÁLEZ-LÓPEZ Tomás-José; KARLSSON Linda Katharina; JIMÉNEZ-LORENZO María-Josefa; HERNÁNDEZ-RIVAS José-Ángel; JAKSIC Ozren; RÁČIL Zdeněk; BUSCA Alessandro; CORRADINI Paolo; HOENIGL Martin; KLIMKO Nikolai; KOEHLER Philipp; PAGLIUCA Antonio; PASSAMONTI Francesco; CORNELY Oliver A
• Year of publication: 2022
• Type: Article in Periodical
• Magazine / Source: Blood
• MU Faculty or unit: Faculty of Medicine
• Web: https://ashpublications.org/blood/article/139/10/1588/477881/COVID-19-in-vaccinated-adult-patients-with
• Doi: http://dx.doi.org/10.1182/blood.2021014124
• Keywords: COVID-19; patients with hematological malignancies; vaccination; EPICOVIDEHA
• Description: Coronavirus disease 2019 (COVID-19) is a life-threatening condition of high relevance for comorbid patients, such as those with baseline hematological malignancies (HM). In April 2020, the European Hematology Association - Infectious Diseases Working Party opened an open web-based registry to collect all cases of HM adult patients that developed COVID-19 infections (EPICOVIDEHA survey). This registry aimed to describe the epidemiology, risk factors, and mortality rates of HM patients. Overall, we collected 3801 valid cases, and we observed an overall mortality rate of 31%.